CTAG2 Antikörper (AA 140-190) (Cy3)
-
- Target Alle CTAG2 Antikörper anzeigen
- CTAG2 (Cancer/testis Antigen 2 (CTAG2))
-
Bindungsspezifität
- AA 140-190
-
Reaktivität
- Human
-
Wirt
- Kaninchen
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser CTAG2 Antikörper ist konjugiert mit Cy3
-
Applikation
- Western Blotting (WB)
- Kreuzreaktivität
- Human
- Aufreinigung
- Purified by Protein A.
- Immunogen
- KLH conjugated synthetic peptide derived from human CTAG2
- Isotyp
- IgG
- Top Product
- Discover our top product CTAG2 Primärantikörper
-
-
- Applikationshinweise
- IF(IHC-P) 1:50-200
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Konzentration
- 1 μg/μL
- Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
- Konservierungsmittel
- Sodium azide
- Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
- Lagerung
- -20 °C
- Informationen zur Lagerung
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
- Haltbarkeit
- 12 months
-
- Target
- CTAG2 (Cancer/testis Antigen 2 (CTAG2))
- Andere Bezeichnung
- Ctag2 (CTAG2 Produkte)
- Synonyme
- CAMEL antikoerper, CT2 antikoerper, CT6.2 antikoerper, CT6.2a antikoerper, CT6.2b antikoerper, ESO2 antikoerper, LAGE-1 antikoerper, LAGE2B antikoerper, cancer/testis antigen 2 antikoerper, CTAG2 antikoerper
- Hintergrund
-
Synonyms: CT2, ESO2, CAMEL, CT6.2, CT6.2a, CT6.2b, LAGE-1, LAGE2B, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1, CTAG2, LAGE1
Background: Testis and very low level in placenta and in some uterus samples. Observed in 25-50 % of tumor samples of melanomas, non-small-cell lung carcinomas, bladder, prostate and head and neck cancers.
- Gen-ID
- 30848
- UniProt
- O75638
-